Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of Monovalent Dengue Vaccine rDEN3Δ30/31-7164
NCT05691530Phase 1Completed
- Sponsor
- National Institutes of Health
- Start
- Mar 2023
- Primary completion
- Apr 2025
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of rDEN3delta30/31-7164 in dengue fever (3 arms), sponsored by National Institutes of Health. Primary endpoints: Number of Participants With Local Adverse Events at 28 days, Number of Participants With Systemic Adverse Events at 28 days and 6 more. Started Mar 2023; status: completed.
02
Drugs
rDEN3delta30/31-7164
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT05691530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05691530.